



## **Vortioxetine a New Generation Serotonin Reuptake Inhibitor in the Treatment of Major Depressive Disorder**

Alaa Alhubaishi (Phram D)

Department of Pharmacy Practice, Princes Nourah bint Abdulrahman University

E-mail: [aaalhubaishi@pnu.sa.edu](mailto:aaalhubaishi@pnu.sa.edu)

### **Abstract**

As depression is one of the rising disorders that are becoming prevalent between people, it had become vital to develop management protocols, which would minimize the symptoms of this disorder with minimal adverse effects to maintain compliance.

Multiple drug groups with different mechanisms of action were developed, however, in conditions related to the central nervous system, it was found that the response towards these medications are variable with regard to safety and efficacy, so all of these groups were investigated to find the available choices for the different medical conditions.

In this article, Vortioxetine, which is a new generation serotonin reuptake inhibitor, was reviewed from different perspectives.

It was concluded based on the review that this drug was approved by FDA and is currently prescribed as a management of the Major Depression Disorder. Researchers had investigated its pharmacological profile. Its other medical uses, and its adverse



events, which, like most of the CNS related medications, were found to be related to psychiatric well-being.

**Keywords:** Serotonin reuptake inhibitor, Serotonin noradrenaline reuptake inhibitor, Serotonin transporters, Major Depressive disorder, Antidepressant, Vortioxetine.

## **Introduction**

One of the main clinical conditions in which just about 30% to 40% of patients accomplish full abatement with first-line treatment of sufficient term is called Major Depressive Disorder (MDD) (Trivedi et al., 2006) and around 33% of patients do not accomplish reduction even after treatment with upwards of four unique antidepressants (Warden, Rush, Trivedi, Fava, & Wisniewski, 2007). Besides, numerous antidepressants are related with symptoms that limit their mediocrity and decrease consistence (Papakostas, 2010). The impediments of existing treatments have prompted calls for better treatment choices for patients with MDD (Rosenzweig-Lipson et al., 2007), a considerable lot of whom encounter drawn out and repetitive burdensome scenes (Gelenberg et al., 2010).

Vortioxetine is an energizer that was endorsed in 2013 in the United States (US) for the treatment of grown-ups with MDD and in the European Union (EU) for the treatment of real burdensome scenes in grown-ups. Vortioxetine contrasts from other at present accessible antidepressants inferable from its multimodal action inside the focal sensory system. Notwithstanding repressing the serotonin (5-HT) transporter (Bang-Andersen et al., 2011), vortioxetine is an opponent at 5-HT<sub>3</sub>, 5-HT<sub>7</sub>, and



5-HT<sub>1D</sub> receptors, an incomplete agonist at 5-HT<sub>1B</sub> receptors, and an agonist at 5-HT<sub>1A</sub> receptors (Westrich et al., 2012).

To date, four free meta-examinations of vortioxetine in patients with MDD have been distributed. Berhan and Barker (2014) led a writing put together investigation centering with respect to contemplate level information from seven companion explored productions of placebo controlled examinations utilizing dosages of 1 to 20 mg/day (Berhan & Barker, 2014). Pae et al. (2015) examined seven companions looked into distributions, four congress modified works, and one clinical examination report of studies utilizing the portions of 1 to 20 mg/day (Pae et al., 2015). Meeker et al. (2015) broke down companion audited productions for eight investigations information from US Food and Drug Administration (FDA) survey records, and [www.ClinicalTrials.gov](http://www.ClinicalTrials.gov) for another 3 thinks about with portions of 1 to 20 mg/day (Meeker, Herink, Haxby, & Hartung, 2015). Each of the three meta-investigations included non-helpful portions of vortioxetine (1 and 2.5 mg/day) and the vortioxetine preliminary in elderly patients (Katona, Hansen, & Olsen, 2012). One utilized the predefined essential endpoints, in view of either the "Montgomery– Åsberg Depression Rating Scale (MADRS) or the Hamilton Depression Rating Scale– 24 thing (HAM-D24)" and all dosages of vortioxetine were crumpled (Pae et al., 2015). Behzadifar et al. (2015) played out a meta-investigation of just examinations with vortioxetine 20 mg/day and fake treatment gatherings (n=4) and results from every preliminary were factually joined utilizing the Mantel– Haenszel arbitrary impacts (Behzadifar et al., 2015).

Based on the aforementioned data, it is concluded that this novel treatment needs to



be examined, this review is displaying the opinions of the researchers based on several opinions.

### **The development of vortioxetine**

In the wake of having effectively presented the specific serotonin (5-HT) reuptake inhibitor (SSRI) antidepressants, numerous pharmaceutical organizations were motivated by preclinical and clinical research in the mid-90s. They show that serotonin transporter (SERT) hindrance joined with hostility of serotonin 1A (5-HT<sub>1A</sub>) somatodendritic autoreceptors brought about an altogether bigger increment of extracellular 5-HT levels in the rat mind and in expanded clinical adequacy, as well as a shorter time to a clinical upper impact contrasted with SSRIs (Artigas, Perez, & Alvarez, 1994; Blier, Bergeron, & de Montigny, 1997). The somatodendritic 5-HT<sub>1A</sub> autoreceptors in the raphe core assume a basic job in the negative criticism direction of 5-HT neurotransmission, and microdialysis and electrophysiology investigations of SSRIs in rodents proposed that desensitization of these receptors was in charge of the watched increment in 5-HT neurotransmission after perpetual SSRI treatment contrasted with the impact of an intense portion. Along these lines, a medication that repressed SERT, irritated 5-HT<sub>1A</sub> autoreceptors or quickened their desensitization through direct receptor incitement, and animated postsynaptic 5-HT<sub>1A</sub> receptors was relied to create an improved 5-HT neurotransmission contrasted with an SSRI and subsequently demonstrate an upgraded clinical reaction. This clinical impact could not be acquired with a quiet 5-HT<sub>1A</sub> receptor foe, since the advantage of upgrading presynaptic 5-HT work was dropped by the synchronous bar of postsynaptic 5-HT<sub>1A</sub> receptors (Scorza et al., 2012). Nonetheless, the scan for medications with



consolidated movement at the SERT and 5-HT<sub>1A</sub> receptors ended up being trying as far as characterizing an ideal strength proportion between the two targets and an ideal practical action at the 5-HT<sub>1A</sub> receptor. Vilazodone, a SERT inhibitor and 5-HT<sub>1A</sub> receptor incomplete (partial) agonist is the main energizer with this objective mix that has made it to the market; it was endorsed by the Food and Drug Administration (FDA) in 2012 for the treatment of MDD.

The medication disclosure program that prompted the revelation and improvement of vortioxetine (1-[2-(2,4-dimethylphenyl-sulfanyl)- phenyl]piperazine, Lu AA21004) (Figure 1) had its birthplaces in the speculation (Artigas, 1993) got from investigations of joined SERT restraint and 5-HT<sub>1A</sub> receptor tweak. Nonetheless, amid the medication disclosure period of the undertaking, the objective profile was diverted toward a mix of SERT restraint, 5-HT<sub>1A</sub> receptor agonism and 5-HT<sub>3</sub> receptor enmity (Bang-Andersen et al., 2011). Consolidated 5-HT<sub>1A</sub> receptor incitement and SERT restraint have been conjectured to prompt quick desensitization of somatodendritic 5-HT<sub>1A</sub> autoreceptors and an upgraded stimulant impact through actuation of post-synaptic 5-HT<sub>1A</sub> receptors (Blier et al., 1997). It was likewise felt that 5-HT<sub>3</sub> receptor enmity may lessen the frequency of sickness saw amid treatment with SSRIs and serotonin and noradrenaline reuptake inhibitors (SNRIs) (Bang-Andersen et al., 2011). Moreover, over the span of the medication revelation program, it was discovered that 5-HT<sub>3</sub> receptor hostility likewise potentiated the expansion in extracellular 5-HT created by SERT bar (Arne Mørk et al., 2013). Vortioxetine was endorsed by the FDA in September 2013 and the European Medicines Agency (EMA) in October 2013 for the treatment of MDD.



As indicated by the Anatomical Therapeutic Classification (ATC) arrangement of the World Health Organization, vortioxetine has a place with the "N06AX Other, Antidepressants" class, which incorporates antidepressants not fitting in to the built up classes of SSRIs, tricyclic antidepressants and monoamine oxidase inhibitors. As per another arrangement framework for psychotropic medications proposed by a Task Force under the European College of Neuropsychopharmacology (ECNP), vortioxetine is an energizer with a multimodal instrument of activity that consolidates adjustment of 5-HT receptor action with restraint of the SERT and vilazodone is delegated a serotonin partial agonist reuptake inhibitor (SPARI) (Zohar et al., 2014). SSRIs and SNRIs are antidepressants with a unimodal component of activity as indicated by this proposed grouping framework, as they act through one target class (monoamine transporter restraint) (Nutt, 2009).




Figure 1 Vortioxetine medicinal structure

### Pharmacological Profile of Vortioxetine



## **Pharmacokinetics**

The pharmacokinetics of vortioxetine are straight and dose-proportional following once day by day organization of 2.5 to 60 mg doses (Areberg, Søggaard, & Højer, 2012; Zhou et al., 2016). Vortioxetine is consumed gradually; however totally, after oral organization and the post-portion crest plasma focus (C<sub>max</sub>) is come to inside 7 to 11 hours (T<sub>max</sub>). The outright bioavailability of vortioxetine is 75%. Nourishment has no impact on the pharmacokinetics of vortioxetine. Vortioxetine is broadly appropriated into the extravascular compartment and has a vast volume of circulation (roughly 2,600 L). The plasma protein restricting is 98%, and is autonomous of plasma fixation.

Vortioxetine is broadly used in the liver, fundamentally through oxidation and ensuing conjugation with glucuronic corrosive. In vitro considers utilizing human liver microsomes and recombinant chemicals have shown that few CYP isoenzymes are engaged with the oxidative biotransformation of vortioxetine, including CYP2D6, CYP3A4/5, CYP2C9, CYP2C19, CYP2A6, CYP2C8 and CYP2B6 (Hvenegaard et al., 2012). Vortioxetine is used to its major carboxylic corrosive metabolite, LuAA34443 (pharmacologically dormant), for the most part by means of the CYP2D6 pathway and poor metabolizers of CYP2D6 accomplish double the plasma groupings of broad metabolizers. A minor hydroxyl metabolite, Lu AA39835, indicates comparative 5-HT transporter restraint to the parent compound however is not relied upon to infiltrate the blood-mind barrier (Chen et al., 2013). The mean end half-life is 66 hours and the mean oral freedom is 33 L/h. around 2/3 of the inert vortioxetine metabolites are discharged through urination and roughly 1/3 in the



defecation. Just unimportant measures of vortioxetine are discharged in the dung. The relentless state plasma focuses are regularly accomplished inside about fourteen days of dosing.

The pharmacokinetics of vortioxetine are not influenced in a clinically important manner by sex, race, renal debilitation "minor, moderate, serious or end-stage renal disease" or gentle or moderate hepatic impairment (Zhou et al., 2016). Vortioxetine has not been concentrated in patients with serious hepatic impedance and alert ought to be practiced while treating these patients. The presentation to vortioxetine expanded by up to 27% (Cmax and AUC) in elderly sound volunteers (matured  $\geq 65$  years) when contrasted with youthful solid control subjects (matured  $\leq 45$  years) getting various portions of 10 mg/day.

### **Pharmacodynamics**

Similarly, as with all as of now accessible upper specialists, the systems hidden the useful impacts of vortioxetine are not completely comprehended. Vortioxetine has an extremely wide scope of pharmacological properties and has been depicted as a "multimodal" energizer. Specifically, vortioxetine is a 5-HT transporter inhibitor, 5-HT<sub>3</sub>, 5-HT<sub>7</sub> and 5-HT<sub>1D</sub> receptor antagonist, 5-HT<sub>1A</sub> receptor agonist 5-HT<sub>1B</sub> receptor fractional agonist (A Mørk et al., 2012; Sanchez, Asin, & Artigas, 2015).

Vortioxetine ties to human 5-HT transporter with high fondness ( $K_i = 1.6$  nM) and strongly and specifically restrains serotonin reuptake ( $IC_{50} = 5.4$  nM) (Bang-Andersen et al., 2011). This pharmacological activity may speak to the key component in charge of its upper impact. Vortioxetine has a much lower fondness to





the human noradrenaline ( $K_i = 113$  nM) and dopamine ( $K_i = 1,000$  nM) transporters (Bang-Andersen et al., 2011). It ties as an agonist to the human 5-HT<sub>1A</sub> receptor with a  $K_i$  of 15 nM, as an incomplete agonist to the human 5-HT<sub>1B</sub> receptor with a  $K_i$  of 33 nM. As also an antagonist to the human 5-HT<sub>3</sub>, 5-HT<sub>7</sub> and 5HT<sub>1D</sub> receptors with  $K_i$  of 3.7 (Guilloux et al., 2013), and 54 nM, respectively (Bang-Andersen et al., 2011).

The net impact of this pharmacological profile is that vortioxetine expands dimensions of 5-HT, noradrenaline, dopamine, acetylcholine, histamine and glutamate in explicit territories of the rodent cerebrum, for example, the ventral hippocampus and the average prefrontal cortex, both known to be imperative in the neurobiology of gloom and reaction to stimulant treatment (Sanchez et al., 2015). This action over a few frameworks might be in charge of the stimulant and anxiolytic-like impacts and the enhancement of subjective capacity, learning and memory saw in creature studies (Guilloux et al., 2013). This wide pharmacological profile may give the method of reasoning to adequacy of vortioxetine in treating patients with real burdensome confusion, including subjective brokenness and summed up uneasiness issue.

### **Effects of Vortioxetine on users' behavior**

As these medications are known to have its impacts on the user's personalities, thoughts and behaviors, multiple researchers had studied its effects on this area. After intense organization, vortioxetine is viable in most standard conduct tests, including the constrained swim test in mice and Flinders Sensitive Line rodents, the



rodent social cooperation test, the rodent adapted dread instigated vocalization test, and the mouse Novelty suppression of feeding test (NSF) and open-field test (OF) (A Mørk et al., 2012). Vortioxetine stays dynamic in the mouse NSF, OF and FST (constrained swim test) in the wake of dosing for 14 and 21 days (Guilloux et al., 2013) and is likewise dynamic in SSRI-obtuse year old C57Black mice treated for multi month (Y Li, Sanchez, & Gulinello, 2013).

Interestingly, vortioxetine was inert in a rodent interminable gentle pressure model of melancholy (Papp, individual correspondence). In this model rehashed presentation to stressors diminishes the admission of a satisfactory 1% sucrose arrangement and lessens DA neurotransmission in the NAc (Papp, 2012). The model is thought to imitate parts of anhedonia, a center side effect of melancholy, and antidepressants, paying little mind to their instrument of activity, are proposed to switch the sucrose admission to control level through sharpening of DA D2/D3 receptors in this model (Willner, 1997). Now vortioxetine's absence of impact in the model has not been researched. Nonetheless, since broad writing recommends that the mesolimbic DA pathway assumes a key job in interceding fortifying impacts of medications and additionally normal rewards, for example, sucrose. Since 5-HT<sub>3</sub> receptors are believed to be imperative middle people of serotonergic adjustment of this pathway (e.g. survey by (Engleman, Rodd, Bell, & Murphy, 2008)), it may be hypothesized that vortioxetine's inability to turn around pressure initiated decrease of sucrose drinking at any rate incompletely is related with its 5-HT<sub>3</sub> receptor hostility. As opposed to these preclinical perceptions, clinical examinations with vortioxetine demonstrate a noteworthy impact of the medication on all things of the



MADRS, including anhedonia (faintness) (Thase, Mahableshwarkar, & Dragheim, 2013). Subsequently, the rodent sucrose-drinking model of anhedonia neglected to anticipate the clinical viability of vortioxetine on this side effect. These disparity likely mirrors the constraints of the sucrose-drinking model as an oversimplified way to deal with explore vortioxetine's impact on a complex clinical manifestation, for example, anhedonia, and option test methodologies would be expected to completely address its impact on anhedonia.

Preclinical and in addition clinical research demonstrate that an unexpected withdrawal of progesterone can create a scope of physical and full of feeling indications including uneasiness, touchiness, anhedonia, social withdrawal and melancholy (Yan Li, Pehrson, Budac, Sánchez, & Gulinello, 2012). Vortioxetine and amitriptyline, in contrast to fluoxetine and duloxetine, created stimulant like practices in the FST in female Long-Evans rodents amid an instigated progesterone withdrawal state (Yan Li, Raaby, Sánchez, & Gulinello, 2013). Past reports show that changes in GABAergic neurotransmission assume a key job in creating the progesterone withdrawal state (Li et al., 2012). Flesinoxan (5-HT<sub>1A</sub> receptor agonist) and ondansetron (5-HT<sub>3</sub> receptor antagonist) have stimulant like action in the progesterone withdrawal demonstrate. Since i) the two receptors can tweak the action of GABAergic neurons, and ii) vortioxetine indicates the two exercises, it very well may be estimated that vortioxetine applies its energizer movement through these receptors and the resulting balance of GABAergic neurotransmission, as proposed by the above electrophysiological examines. Along these lines, it creates the impression that vortioxetine may intercede its energizer action by connection



with focuses on that vary from those of SSRIs and SNRIs.

## **Conclusion**

Based on the reviewal of the aforementioned points, it is confirmed that vortioxetine is one of the promising antidepressant agents that has its effects on serotonin, GABA, dopamine, noradrenaline and multiple different neurotransmitters which have its role in the health of central nervous system and deposition changes. It is now used and prescribed by psychiatrics, and it is approved by FDA.

Its pharmacological profile was studied, developed including pharmacokinetics, and pharmacodynamic, and it was found to be stable and possible to study these properties of it.

Like all of the medications, it has adverse effects; however, the most recognized adverse events are those, which are related to depression and psychological well-being, which is well known within such medication groups. Based on the studies, it was found that a main use of this medication could be the management of depression in menopausal women after progesterone levels decline.

More examinations are needed, as there are several other points' needs to be confirmed, and other issues, which needs to be studied and discussed.



## References

- Areberg, J., Søgaaard, B., & Højer, A. M. (2012). The clinical pharmacokinetics of Lu AA21004 and its major metabolite in healthy young volunteers. *Basic & clinical pharmacology & toxicology*, *111*(3), 198-205.
- Artigas, F. (1993). 5-HT and antidepressants: new views from microdialysis studies. *Trends in Pharmacological Sciences*, *14*(7), 262.
- Artigas, F., Perez, V., & Alvarez, E. (1994). Pindolol induces a rapid improvement of depressed patients treated with serotonin reuptake inhibitors. *Archives of General Psychiatry*, *51*(3), 248-251.
- Bang-Andersen, B., Ruhland, T., Jørgensen, M., Smith, G., Frederiksen, K., Jensen, K. G., . . . Mørk, A. (2011). Discovery of 1-[2-(2, 4-dimethylphenylsulfanyl) phenyl] piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder. *Journal of medicinal chemistry*, *54*(9), 3206-3221.



- Behzadifar, M., Dehghan, H., Saki, K., Behzadifar, M., Keshavarzi, A., Saran, M., & Sari, A. A. (2015). Evaluation efficacy and safety of Vortioxetine 20 mg/d versus placebo for treatment Major Depressive Disorder: A systematic review and meta-analysis of randomized controlled trials. *Pharmacology & Pharmacy*, 6(04), 221.
- Berhan, A., & Barker, A. (2014). Vortioxetine in the treatment of adult patients with major depressive disorder: a meta-analysis of randomized double-blind controlled trials. *BMC psychiatry*, 14(1), 276.
- Blier, P., Bergeron, R., & de Montigny, C. (1997). Selective activation of postsynaptic 5-HT 1A receptors induces rapid antidepressant response. *Neuropsychopharmacology*, 16(5), 333.
- Chen, G., Lee, R., Højer, A.-M., Buchbjerg, J. K., Serenko, M., & Zhao, Z. (2013). Pharmacokinetic drug interactions involving vortioxetine (Lu AA21004), a multimodal antidepressant. *Clinical drug investigation*, 33(10), 727-736.
- Engleman, E., Rodd, Z., Bell, R., & Murphy, J. (2008). The role of 5-HT<sub>3</sub> receptors in drug abuse and as a target for pharmacotherapy. *CNS & Neurological Disorders-Drug Targets (Formerly Current Drug Targets-CNS & Neurological Disorders)*, 7(5), 454-467.
- Gelenberg, A., Freeman, M., Markowitz, J., Rosenbaum, J., Thase, M., Trivedi, M., & Van Rhoads, R. (2010). Work Group on Major Depressive Disorder. Practice Guideline for the Treatment of Patients With Major Depressive Disorder. 3rd ed. Arlington, VA: American Psychiatric Association.
- Guilloux, J.-P., Mendez-David, I., Pehrson, A., Guiard, B. P., Repérant, C., Orvoën, S., . . . Miller, S. (2013). Antidepressant and anxiolytic potential of the multimodal



- antidepressant vortioxetine (Lu AA21004) assessed by behavioural and neurogenesis outcomes in mice. *Neuropharmacology*, 73, 147-159.
- Hvenegaard, M. G., Bang-Andersen, B., Pedersen, H., Jorgensen, M., Puschl, A., & Dalgaard, L. (2012). Identification of the cytochrome P450 and other enzymes involved in the in vitro oxidative metabolism of a novel antidepressant, Lu AA21004. *Drug Metabolism and Disposition*, dmd. 112.044610.
- Katona, C., Hansen, T., & Olsen, C. K. (2012). A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder. *International clinical psychopharmacology*, 27(4), 215-223.
- Li, Y., Pehrson, A. L., Budac, D. P., Sánchez, C., & Gulinello, M. (2012). A rodent model of premenstrual dysphoria: progesterone withdrawal induces depression-like behavior that is differentially sensitive to classes of antidepressants. *Behavioural brain research*, 234(2), 238-247.
- Li, Y., Raaby, K. F., Sánchez, C., & Gulinello, M. (2013). Serotonergic receptor mechanisms underlying antidepressant-like action in the progesterone withdrawal model of hormonally induced depression in rats. *Behavioural brain research*, 256, 520-528.
- Li, Y., Sanchez, C., & Gulinello, M. (2013). P. 1. j. 002 Memory impairment in old mice is differentially sensitive to different classes of antidepressants. *European Neuropsychopharmacology*, 23, S282.
- Meeker, A. S., Herink, M. C., Haxby, D. G., & Hartung, D. M. (2015). The safety and efficacy of vortioxetine for acute treatment of major depressive disorder: a systematic review and meta-analysis. *Systematic reviews*, 4(1), 21.



- Mørk, A., Montezinho, L. P., Miller, S., Trippodi-Murphy, C., Plath, N., Li, Y., . . . Sanchez, C. (2013). Vortioxetine (Lu AA21004), a novel multimodal antidepressant, enhances memory in rats. *Pharmacology Biochemistry and Behavior*, 105, 41-50.
- Mørk, A., Pehrson, A., Brennum, L. T., Nielsen, S. M., Zhong, H., Lassen, A. B., . . . Sanchez, C. (2012). Pharmacological effects of Lu AA21004: a novel multimodal compound for the treatment of major depressive disorder. *Journal of Pharmacology and Experimental Therapeutics*, 340(3), 666-675.
- Nutt, D. (2009). Beyond psychoanaleptics—can we improve antidepressant drug nomenclature? *Journal of Psychopharmacology*, 23(4), 343-345.
- Pae, C.-U., Wang, S.-M., Han, C., Lee, S.-J., Patkar, A. A., Masand, P. S., & Serretti, A. (2015). Vortioxetine: a meta-analysis of 12 short-term, randomized, placebo-controlled clinical trials for the treatment of major depressive disorder. *Journal of psychiatry & neuroscience: JPN*, 40(3), 174.
- Papakostas, G. I. (2010). The efficacy, tolerability, and safety of contemporary antidepressants. *The Journal of clinical psychiatry*, 71, e03-e03.
- Papp, M. (2012). Models of affective illness: chronic mild stress in the rat. *Current protocols in pharmacology*, 57(1), 5.9. 1-5.9. 11.
- Rosenzweig-Lipson, S., Beyer, C. E., Hughes, Z. A., Khawaja, X., Rajarao, S. J., Malberg, J. E., . . . Schechter, L. E. (2007). Differentiating antidepressants of the future: efficacy and safety. *Pharmacology & therapeutics*, 113(1), 134-153.
- Sanchez, C., Asin, K. E., & Artigas, F. (2015). Vortioxetine, a novel antidepressant with multimodal activity: review of preclinical and clinical data. *Pharmacology & therapeutics*, 145, 43-57.





- Scorza, M. C., Lladó- Pelfort, L., Oller, S., Cortes, R., Puigdemont, D., Portella, M., . . . Perez, V. (2012). Preclinical and clinical characterization of the selective 5-HT<sub>1A</sub> receptor antagonist DU- 125530 for antidepressant treatment. *British journal of pharmacology*, 167(5), 1021-1034.
- Thase, M. E., Mahableshwarkar, A., & Dragheim, M. (2013). The efficacy of vortioxetine vs placebo in the treatment of adults with major depressive disorder: patient level data from 10 short-term studies and a meta-analysis. Paper presented at the Neuropsychopharmacology.
- Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., . . . McGrath, P. J. (2006). Evaluation of outcomes with citalopram for depression using measurement-based care in STAR\* D: implications for clinical practice. *American journal of Psychiatry*, 163(1), 28-40.
- Warden, D., Rush, A. J., Trivedi, M. H., Fava, M., & Wisniewski, S. R. (2007). The STAR\* D Project results: a comprehensive review of findings. *Current psychiatry reports*, 9(6), 449-459.
- Westrich, L., Pehrson, A., Zhong, H., Nielsen, S. M., Frederiksen, K., Stensbol, T. B., . . . Sanchez, C. (2012). In vitro and in vivo effects of the multimodal antidepressant vortioxetine (Lu AA21004) at human and rat targets. Paper presented at the *International Journal of Psychiatry in Clinical Practice*.
- Willner, P. (1997). The mesolimbic dopamine system as a target for rapid antidepressant action. *International clinical psychopharmacology*.
- Zhou, X., Hu, X., Wu, S., Ye, J., Sun, M., Gu, J., . . . Zhang, Z. (2016). Structures and physicochemical properties of vortioxetine salts. *Acta Crystallographica Section B: Structural Science, Crystal Engineering and Materials*, 72(5), 723-732.



[www.mescj.com](http://www.mescj.com)

Zohar, J., Nutt, D. J., Kupfer, D. J., Moller, H.-J., Yamawaki, S., Spedding, M., & Stahl, S. M. (2014). A proposal for an updated neuropsychopharmacological nomenclature. *European Neuropsychopharmacology*, 24(7), 1005-1014.